Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis

  • Authors:
    • Miao Liu
    • Qin‑Guo Mo
    • Chang‑Yuan Wei
    • Qing‑Hong Qin
    • Zhen Huang
    • Jie He
  • View Affiliations

  • Published online on: December 28, 2012     https://doi.org/10.3892/ol.2012.1093
  • Pages: 983-991
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple‑negative breast cancer (TNBC) tumors do not express estrogen, progesterone or HER2/neu‑receptors. There are no specific treatment guidelines for TNBC patients, however, it has been postulated that their phenotypic and molecular similarity to BRCA1‑associated cancers would confer sensitivity to certain cytotoxic agents, including platinum. The aim of this meta‑analysis was to evaluate the clinical outcome of breast cancer patients treated with platinum‑based chemotherapy who had TNBC compared with those with non‑TNBC. Electronic (MEDLINE, EMBASE and Cochrane Library databases) and manual searches were conducted throughout December 2011 to identify trials evaluating the use of platinum‑based chemotherapy for patients with breast cancer. The methodological quality was assessed in accordance with the QUOROM statement. Seven studies met the eligibility criteria, with a total of 717 patients. Of these patients, 225 were TNBC patients (31%), 492 were non‑TNBC patients (69%), 275 received platinum‑based neo‑adjuvant chemotherapy and 442 had advanced/metastatic breast cancers. The results showed that during neo‑adjuvant chemotherapy, the clinical complete response (cCR) rate and the pathological complete response (pCR) rates were significantly higher for the TNBC group compared with the non‑TNBC group (OR, 2.68; 95% CI, 1.69‑6.57; P=0.03 and OR, 2.89; 95% CI, 1.28, 6.53; P=0.01, respectively). However, in advanced/metastatic breast cancers, the cCR, partial response (PR) and the disease control rates for the TNBC group were not significantly different compared with the non‑TNBC group. The 6-month progression‑free survival (PFS) rate for the TNBC group was higher than that of the non‑TNBC group in all patients (OR, 1.81; 95% CI, 1.11‑2.96; P=0.02). However, the 1‑ and 2‑year PFS rates were not significantly different (OR, 1.42; 95% CI, 0.69‑2.92; P=0.35 and OR, 1.11; 95% CI, 0.35‑3.52; P=0.85, respectively). Furthermore, the PFS rates were not significantly different between the groups in patients with advanced/metastatic breast cancer. In conclusion, platinum‑based chemotherapy in the breast cancer patients with TNBC showed an improved short‑term efficacy compared with the non‑TNBC group during neo‑adjuvant chemotherapy, but has not yet been demonstrated to have an improved effect in advanced breast cancer.
View Figures
View References

Related Articles

Journal Cover

March 2013
Volume 5 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu M, Mo QG, Wei CY, Qin QH, Huang Z and He J: Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis. Oncol Lett 5: 983-991, 2013
APA
Liu, M., Mo, Q., Wei, C., Qin, Q., Huang, Z., & He, J. (2013). Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis. Oncology Letters, 5, 983-991. https://doi.org/10.3892/ol.2012.1093
MLA
Liu, M., Mo, Q., Wei, C., Qin, Q., Huang, Z., He, J."Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis". Oncology Letters 5.3 (2013): 983-991.
Chicago
Liu, M., Mo, Q., Wei, C., Qin, Q., Huang, Z., He, J."Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis". Oncology Letters 5, no. 3 (2013): 983-991. https://doi.org/10.3892/ol.2012.1093